Submitted by BC Government
PharmaCare launched the Biosimilars Initiative on May 24, 2019 with the goal of switching patients using Enbrel®, Remicade®, and Lantus® to the biosimilar versions of these medications by November 22, 2019. The three biologic drugs affected are among the largest drug expenditures in the province, totalling $125 million in 2018. Meanwhile, approved biosimilar versions that are more cost-effective and just as safe and effective are underused. The Biosimilars Initiative is a result of PharmaCare’s evidence-informed strategy to better optimize our public resources, getting the best value for new treatments and services.
More information is available at gov.bc.ca/biosimilars/prescribers.